Adage Capital Management

Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&P index in each of the last 15 years by an average of 3.5%. The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..
RG

Robert George Atchinson

Co-Founder, MD and Portfolio Manager

60 past transactions

goPuff

Series H in 2021
goPuff is a service that is replacing the need for convenience stores. The company warehouses and delivers thousands of products in 20-30 minutes to your door 24/7, for a flat $1.95 delivery charge. As the fastest and most affordable on-demand delivery option available in the market, goPuff takes convenience seriously, bringing you what you need, when you need it, operating from 12 PM to 4:30am in some cities and 24/7 in others. goPuff's backend system and warehouses streamline supply chain and make the model scalable. goPuff currently operates in 33 US markets and continues to expand rapidly.

Ambrx, Inc.

Private Equity Round in 2020
Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

WellDoc

Series B in 2015
WellDoc is developing the next generation of technology solutions to support chronic disease management. Its mission is to improve the lives of people with chronic diseases they fulfill their mission by integrating clinical, behavioral, and motivational applications with everyday technologies, like the internet and cell phone, to engage patients and healthcare providers in ways that dramatically improve outcomes and significantly reduce healthcare costs. It was founded in 2005 and headquartered in Columbia, Maryland.

Arch Oncology, Inc.

Series C in 2021
At Arch Oncology, they are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. They are committed to advancing antibodies with best-in-class potential.Their next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.

ImaginAb, Inc.

Venture Round in 2017
ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized for clinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics.

Tanium

Private Equity Round in 2018
Tanium is a security and systems management platform that allows real-time data collection at an enterprise scale. It provides enterprise and government organizations with tools to secure, control, and manage millions of endpoints across the enterprise within seconds. The platform allows security and IT operations teams to get access to visibility and accurate information on the state of endpoints at all times to protect against modern-day disruptions and realize new levels of business resilience. Tanium was founded by David Hindawi and Orion Hindawi in 2007 and is headquartered in Kirkland, Washington, United States.

HemoShear Therapeutics

Series A in 2021
HemoShear Therapeutics develops new treatments for patients with rare metabolic disorders. It creates human-relevant systems to accurately replicate the biology of organ systems and diseases for use throughout drug discovery and development. They work strategically in partnerships with pharmaceutical, biotechnology, and medical device companies. It generates meaningful human response data to increase confidence in decision-making, reduce the risk of costly failures, and identify efficacious therapies.

Annexon, Inc.

Post in 2022
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company’s candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.

ConnectRN, Inc.

Venture Round in 2021
ConnectRN, Inc. operates an online platform for hospitals and healthcare institutions to communicate with available nurses. The company’s platform provides various tools to connect healthcare providers to qualified and available staff via an alert system that is sent to their mobile devices. Its nurse management Web dashboard streamlines communication between nurses and nurse managers to ensure open shifts are filled. ConnectRN, Inc. was incorporated in 2014 and is based in Newton, Massachusetts.
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Scout Bio, Inc.

Series B in 2019
Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Scout Bio, Inc.

Series B in 2021
Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.
EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

HawkEye 360

Series C in 2021
HawkEye 360 is a data analytics company that develops space-based radio frequency mapping. The company operates a commercial satellite constellation to identify, process, and geolocate a broad set of RF signals. Its products include maritime domain awareness and spectrum mapping and monitoring; our customers include a wide range of commercial, government, and international entities. The company was founded in 2015 and is headquartered in Herndon, Virginia.

Pyramid Biosciences, Inc.

Series B in 2021
Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient’s disease, condition, or symptoms.

Rapid Micro Biosystems, Inc.

Private Equity Round in 2021
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Vapotherm

Series C in 2015
Vapotherm, Inc. is a privately held company based in Exeter, New Hampshire, dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification.

Aimmune Therapeutics

Series B in 2015
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

GOAT

Series F in 2021
GOAT Group is the world’s largest marketplace for authentic sneakers. Its brands offer the greatest selection of sneakers available through company-operated retail stores, e-commerce sites and mobile apps under the GOAT and Flight Club brands. Through its innovative technology and service, GOAT Group has changed the landscape of sneaker commerce and has quickly become the world’s most trusted source to discover, buy and sell authentic sneakers. The company is backed by strategic investor Foot Locker, Inc. as well as some of the leading names in venture capital including Accel, Andreessen Horowitz, Index Ventures, Matrix Partners, Upfront Ventures, Webb Investment Network and Y Combinator.

Stem, Inc.

Post in 2021
Stem brings and optimizes energy consumption to business through its distributed storage technology. Since 2009, Stem has been analyzing how various types of businesses use electricity and how they are charged for it. The company uses this information to design a solution that protects companies from unnecessarily high electricity costs without requiring any changes to the way they run their businesses. Stem combines big data, predictive analytics and energy storage to reduce electric costs for businesses and in aggregate, deliver services to the grid.

Menlo Micro

Series C in 2022
Menlo Micro is a developer of an electromechanical switch technology used to offer products ranging from battery chargers to electric vehicles. The company's products can handle high temperatures and high-stress conditions and help in battery management, home automation, and medical instrumentation that enable clients to work with advanced products and deliver efficient outcomes using high power. Menlo Micro was founded in 2016 and is headquartered in Irvine, California.

Zafgen

Post in 2021
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

SiMa Technologies, Inc.

Series B in 2021
SiMa Technologies, Inc. designs and develops a machine learning platform that provides single-chip solution for embedded systems. It offers Machine Learning SoC, a platform that supports traditional computing with machine learning inference; and machine learning solutions ranging from 50 TOPs@5W to 200 TOPs@20W. The company’s solution also detects hackers and other threats. SiMa Technologies, Inc. was incorporated in 2018 and is based in San Jose, California.
Flywire develops a vertical payments platform designed to simplify the global payment and receivables process. Its platform utilizes vertical-specific insight and technology to optimize the payment experience while eliminating operational challenges from invoicing to payment reconciliation, enabling organizations to improve operational efficiency and protect their customers from fraudulent activity. The company was founded in 2011 and is headquartered in Boston, Massachusetts.
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Forter

Series F in 2021
Forter is an NYC-based company that delivers real-time, completely automated, fraud prevention solutions for online merchants. It creates a completely fraud-free environment for the retailers through which they have the ability to make decisions that are solely based on what is good for their business. The company’s system is designed to be consumer-centric, blocking fraud with accuracy, and at the same time enabling growth by increasing approvals and ensuring a better customer experience.

Advanced Accelerator Applications

Venture Round in 2015
Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products. AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

Energy Vault SA

Post in 2022
Energy Vault SA offers an energy storage technology utilizing fundamental principles of science to deliver a storage solution that's as compassionate to the planet as it is efficient to build and operate. The Energy Vault solution utilizes the same fundamentals of physics and kinetic energy as pumped hydro but replaces the water with custom made cylindrical blocks utilizing an extremely innovative use of low-cost materials. The system is modular and can be designed with a capacity of between 10 and 35MWh and a power output of up to 5MW. The system has been designed for a 30+ year life with no degradation in storage capacity.

ViaCyte, Inc.

Series D in 2021
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.

Beckley Psytech

Series B in 2021
Beckley Psytech Limited manufactures psychedelic drug for treating psychiatric and neurological diseases. Beckley Psytech Limited was formerly known as Beckley Psychedelics Limited and changed its name to Beckley Psytech Limited in May 2020. The company was founded in 2014 and is based in Oxford, United Kingdom.
Novus Therapeutics is a pharmaceutical company focusing on the acquisition, development, and commercialization of ear, nose, and throat (ENT) products. The company has two technologies, each of which has the potential to be developed for multiple ENT indications. It was founded in 2004 and headquartered in Irvine, California.

ImaginAb, Inc.

Venture Round in 2021
ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized for clinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics.

Annexon, Inc.

Series C in 2018
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company’s candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

Cabaletta Bio, Inc.

Series A in 2018
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.

Advaxis

Post in 2015
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

Pulmonx

Series H in 2020
Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The company’s Zephyr® Endobronchial Valve (EBV) therapy* involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung. The company has CE mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System. The company has 510(k) marketing clearance for the Chartis System in the United States.

Protagonist Pty Ltd

Series C in 2015
Protagonist Pty Ltd. develops novel therapeutics for inflammatory and metabolic conditions. The company also involves in the discovery of peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. In addition, it focuses on the discovery of drug candidates for targets previously resistant to small molecule discovery (protein-protein interactions), and on designing and constructing arrays of molecules that sample biologically-relevant regions of chemical diversity. Protagonist Pty Ltd was formerly known as Cytokine Mimetics Pty Ltd. The company was founded in 2001 and is based in Brisbane, Australia. Protagonist Pty Ltd operates as a subsidiary of Protagonist Therapeutics, Inc.

Vapotherm

Series B in 2014
Vapotherm, Inc. is a privately held company based in Exeter, New Hampshire, dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification.

Calithera Biosciences

Series D in 2013
Calithera is a development stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.

PTC Therapeutics, Inc.

Private Equity Round in 2013
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Flywire develops a vertical payments platform designed to simplify the global payment and receivables process. Its platform utilizes vertical-specific insight and technology to optimize the payment experience while eliminating operational challenges from invoicing to payment reconciliation, enabling organizations to improve operational efficiency and protect their customers from fraudulent activity. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Vapotherm

Series C in 2015
Vapotherm, Inc. is a privately held company based in Exeter, New Hampshire, dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification.

Ultragenyx Pharmaceutical

Series B in 2012
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

Nexvet Australia Pty Ltd

Series B in 2014
Nexvet Australia Pty Ltd, a biopharmaceutical company, develops biological therapies for companion animals. It develops drugs in the areas of chronic pain, immune oncology, chronic inflammation, and allergy. Nexvet Australia Pty Ltd was formerly known as Nexvet Biopharma Pty Ltd. The company was founded in 2010 and is based in Melbourne, Australia with a biopharmaceutical manufacturing facility in Tullamore, Ireland. Nexvet Australia Pty Ltd operates as a subsidiary of Zoetis Inc.

Puma Biotechnology, Inc.

Private Equity Round in 2011
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Pyramid Biosciences, Inc.

Venture Round in 2020
Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient’s disease, condition, or symptoms.

Flame Biosciences, Inc

Venture Round in 2020
Flame Biosciences, Inc operates as a clinical stage company that engages in the research, development, and commercialization of transformative therapies for cancer and other inflammatory conditions. It offers FL-101 therapy for the treatment of lung cancers that are driven by inflammation; and FL-201 for reducing the chronic inflammation in patients. The company was incorporated in 2017 and is based in New York, New York.

MedAvail Holdings, Inc

Series C in 2014
MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississauga, Canada.

Lumena Pharmaceuticals

Series B in 2014
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

Cabaletta Bio, Inc.

Series B in 2019
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.
Adverum Biotechnologies, formerly Avalanche Biotechnologies, is a gene therapy company. The company focuses on discovering and developing medicines that can offer therapeutic benefits to patients dealing with a chronic or debilitating disease. The company was formed after the merger of Avalanche Biotechnologies and Annapurna Therapeutics in May 2016.

MedAvail Holdings, Inc

Series D in 2018
MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississauga, Canada.

Prevail Therapeutics

Series A in 2018
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

ZS Pharma, Inc.

Series D in 2014
ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

Prevail Therapeutics

Series B in 2019
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Engage Therapeutics

Series A in 2017
Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures. Staccato alprazolam in a Phase 2a proof of concept study demonstrated reduction of seizure in a photosensitivity model. The product will proceed into an advanced clinical setting leveraging a 505(b)(2) regulatory pathway.